Dr. Zuckerman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
190 E Bannock St
Boise, ID 83712Phone+1 208-381-2790Fax+1 208-381-4025- Is this information wrong?
Summary
- Dr. Dan Zuckerman is the executive medical director of St. Luke's Mountain States Tumor Institute (MSTI) in Boise, ID. He received his medical degree from University of Chicago Pritzker School of Medicine and trained at Brigham and Women's Hospital and Dana-Farber Cancer Institute and has been in practice 15 years. He specializes in gastrointestinal cancer.
Clinical Expertise
- Gastrointestinal oncology, Hematologic oncology
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2005 - 2008- Brigham and Women's HospitalResidency, Internal Medicine, 2002 - 2005
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2002
Certifications & Licensure
IL State Medical License 2023 - 2026
CA State Medical License 2024 - 2026
TN State Medical License 2023 - 2025
DE State Medical License 2022 - 2025
SD State Medical License Active through 2025
WV State Medical License 2023 - 2025
WI State Medical License 2023 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
- Join now to see all
Awards, Honors, & Recognition
- Phi Beta Kappa Williams College
- Alpha Omega Alpha University of Chicago Pritzker School of Medicine
Clinical Trials
- Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer Start of enrollment: 2007 Jun 01
- Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
- T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) Start of enrollment: 2013 May 01
- Join now to see all
Publications & Presentations
PubMed
- 8 citationsCardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TB...Romualdo Barroso-Sousa, Paolo Tarantino, Nabihah Tayob, Chau Dang, Denise A Yardley, Steven J Isakoff, Vicente Valero, Meredith Faggen, Therese Mulvey, Ron Bose, Jiani...> ;NPJ Breast Cancer. 2022 Feb 16
- 15 citationsChemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Tr...Kathryn J. Ruddy, Yue Zheng, Nabihah Tayob, Jiani Hu, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose,...> ;Breast Cancer Research and Treatment. 2021 Jun 12
- 65 citationsAdjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical TrialSara M. Tolaney, Nabihah Tayob, Chau T. Dang, Denise A. Yardley, Steven J. Isakoff, Vicente Valero, Meredith Faggen, Therese M. Mulvey, Ron Bose, Jiani Hu, Douglas Wec...> ;Journal of Clinical Oncology. 2021 Jun 2
- Join now to see all
Press Mentions
Perry Brown and Dan Zuckerman: Laws Criminalizing Medical Care Are Weakening Health Care for IdahoansMarch 11th, 2023- Delays in CT Imaging for Cancer Still Persist After COVID-19 Pandemic, Study FindsNovember 24th, 2021
- With Hospitals Crowded from COVID, 1 in 5 American Families Delays Health CareOctober 14th, 2021
- Join now to see all
Professional Memberships
- Member
Hospital Affiliations
St. Luke's Boise Medical CenterBoise, Idaho
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
